2 unknown. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
| Phase 1 | 1 | Unknown 1 |
Follow BioSight Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML BST-236, venetoclax - AML, Adult | Phase 1 / Phase 2 | Unknown | BioSight Ltd. | 80 | 2022-08-17 | 2023-04-04 |
| Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS BST-236 - AML, Adult, MDS | Phase 2 | Unknown | BioSight Ltd. | 40 | 2021-11-14 | 2023-03-09 |
Leukemia, Myeloid, Acute (2) · Recurrence (1)
venetoclax (1)
United States (2)